loading
  • Trang chủ
  • Sách, tuyển tập
  • High-dose deferoxamine treatment [intravenous] for thalassaemia patients with cardiac complications / Ghader, F.R.;Kousarian, M.;Farzin, D.
Sách, tuyển tập

High-dose deferoxamine treatment [intravenous] for thalassaemia patients with cardiac complications / Ghader, F.R.;Kousarian, M.;Farzin, D.

Tác giả : Ghader, F.R.;Kousarian, M.;Farzin, D.

Năm xuất bản : 2007

Chủ đề : 1. Cardiomyopathies. 2. Deferoxamine. 3. Ferritins. 4. Thalassemia. 5. Treatment Outcome.

Chia sẻ

Thông tin chi tiết

Tóm tắt :

1053-1059 As a means to manage cardiac conditions, we determined the effects of high-dose intravenous [IV] deferoxamine in 15 thalassaemia patients with cardiomyopathy and high ferritin and haemoglobin levels. The patients received IV deferoxamine, 130 mg/kg per day over 10-14 hours [maximum 5 g] for 5 consecutive days. All patients underwent a full evaluation before receiving deferoxamine, and 2 days and 1 month after completing the treatment. Visual and auditory examinations were done to detect any side-effects. After treatment, cardiovascular symptoms decreased considerably and systolic function showed significant improvement, but there was no significant effect on diastolic function, electro-cardiography and physical findings. There were no significant side-effects reported
Chia sẻ


Hiển thị MARC

 Thông tin dữ liệu nguồn

 Thư viện  Ký hiệu xếp giá  Dữ liệu nguồn
Tổ chức y tế thế giới
https://iris.who.int/handle/10665/117346